A Study of IBI363 in Subjects With Advanced Melanoma
A phase 2 trial of IBI363 in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Overview
A Study of IBI363 in Subjects With Advanced Melanoma is a phase 2 interventional study registered as NCT06081920 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2023-10-19 and due to reach its primary completion in 2028-10-19. Interventions recorded: IBI363. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Setting
A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma
Phase
Phase 2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Registry
Enrolled
180
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat
Shares IBI363, Innovent Biologics, Melanoma.
- TrialA Study of IBI363 in Subjects with Advanced Solid Malignancies
Shares IBI363, Innovent Biologics, Melanoma.
- TrialIBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Shares IBI363, Innovent Biologics.
- TrialIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small
Shares IBI363, Innovent Biologics.